REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils : The REDES Study
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Carrillo Díaz, Teresa (Universidad de Las Palmas de Gran Canaria)
Blanco Aparicio, Marina (H. Universitario A Coruña)
Martínez Moragón, Eva (H. Universitario Doctor Peset, Valencia)
Bañas-Conejero, David (GlaxoSmithKline. Specialty Care Medical Department)
Sánchez Herrero, M. Guadalupe (GlaxoSmithKline. Specialty Care Medical Department)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2021
Abstract:	The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits the generalizability of results. Our study evaluated the effectiveness and safety of mepolizumab in patients with SEA in Spain. The primary efficacy endpoint was the change in the rate of clinically significant asthma exacerbations 12 months after starting mepolizumab compared to the baseline rate in the 12 months prior to treatment. Patients were stratified by baseline blood eosinophil counts. We conducted a multicentric observational cohort study of SEA patients treated with mepolizumab across 24 specialized hospital asthma units in Spain. Severe exacerbation rate, lung function, oral corticosteroid use (OCS) and asthma control test (ACT) were retrospectively collected and compared during the 12-month pre- and post-mepolizumab treatment. Adverse events were also investigated. A total of 318 patients with SEA were included (mean age: 56. 6 years, 69. 2% female). Exacerbation rates decreased by 77. 5%, and 50. 6% of patients did not suffer any exacerbations during the 12 months of treatment. The difference in forced expiratory volume in 1 s (FEV1) pre- and post-bronchodilator after starting mepolizumab was 0. 21 (0. 46) L (95% CI 0. 14-0. 27) (p < 0. 001). Exacerbations and lung function significantly improved across all eosinophil subgroups. Among the 98 patients on OCS, 47. 8% were able to discontinue this treatment and the mean daily dose was decreased by 59. 9%. The baseline ACT score was 14. 1, increasing by a mean (SD) of 6. 7 points (1. 9) at 12 months. Adverse events related to mepolizumab were uncommon. This real-world study of SEA patients confirms that mepolizumab is effective in reducing clinically meaningful exacerbations, improving lung function, and decreasing OCS dependence and mean OCS dose at 12 months, irrespective of baseline eosinophil counts.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Drugs, Vol. 81 (september 2021) , p. 1763-1774, ISSN 1179-1950

DOI: 10.1007/s40265-021-01597-9
PMID: 34586602

Article 12 p, 1.1 MB

Correcció 3 p, 455.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles